Effects of Biofermin-R Administered in Combination with Antibiotics on the Fecal Flora

Yamashita, Masayuki; Hatano, Mamoru; Nakamura, Hajime; Murakami, Ryusuke; Matsuo, Masafumi; Matsuo, Tamotsu; Kumon, Yasushi

doi:10.12938/bifidus1982.4.1_23

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ozawa (1985) has also reported that Enterococcus faecalis suppressed the proliferation of putrefactive organisms such as Salmonella and yeast in the intestinal tract. Yamashita et al (1985) has again reported that the administration of Streptococcus preparation suppressed the proliferation of putrefactive bacteria. In conclusion, B. bifidum OFR9 is a good lactic acid bacterium having the original biochemical characteristics of bifidobacteria as well as high resistance to antituberculosis and antileprosy agents.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

The effects of Bifidobacterium bifidum OFR9, a strain resistant to antituberculosis and antileprosy agents, on fecal flora in mice.

Chung

Kim

Choi

1997

J. Gen. Appl. Microbiol.

View full text Add to dashboard Cite

Since Bifidobacterium bifidum, one of the strains of medical preparations used for human intestinal disorders, is sensitive to rifampicin (RFP) and fluoroquinolones, its therapeutic effect cannot be guaranteed when it is administered concomitantly with these antibiotics. To develop new strains of B. bifidum that are resistant to these drugs, B. bifidum RFR61, which is highly resistant to RFP, was selected by the N-methyl-N'-nitrosoguanidine (MNNG) mutation method. Then, B. bifidum OFR9 was selected in vitro from B. bifidum RFR61 by serial passage to increasing concentrations of oflloxacin (OFLX) on a solid medium. The minimal inhibition concentrations (MIC) of RFP and fluoroquinolones for B. bifidum OFR9 were >256 µg/ml and 16-256 µg/ml, respectively. We investigated the effects of B. bifidum OFR9 on the fecal bacterial flora of mice administered with both antibiotics and B. bifidum OFR9. The results showed that the concurrent use of B. bifidum OFR9 and antibiotics prevented the decrease of bifidobacteria, and quickly restored the flora to normal as compared with the use of antibiotic or parent strain therapy alone. The survival of Shigella organisms in mouse feces rapidly decreased, and were removed within two days as a result of the oral administration of B. bifidum OFR9.

show abstract

Section: Discussionmentioning

confidence: 94%

“…2). Yamashita et al (1985) reported that when ampicillin was administered to mice with Biofermin-R, multiresistant Streptococcus preparations, bifidobacteria recovered earlier and reached normal more quickly than in the case of ampicillin treatment alone.…”

Section: Minimal Inhibition Concentrationmentioning

confidence: 99%

The effects of Bifidobacterium bifidum OFR9, a strain resistant to antituberculosis and antileprosy agents, on fecal flora in mice.

Chung

Kim

Choi

1997

J. Gen. Appl. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Biofermin‐R (BFR) comprises of Enterococcus faecium 129 BIO 3B‐R. It is a multiple antibiotic‐resistant lactic acid bacteria preparation, which is known to normalize the fecal flora when used in combination with ampicillin and cephalexin 12 . However, its effect on the gut microbiota and any associated adverse events during VPZ‐containing triple therapy remain unexplored.…”

Section: Introductionmentioning

confidence: 99%

Effect of probiotics during vonoprazan‐containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial

Kakiuchi

Mizoe²,

Yamamoto

et al. 2020

Helicobacter

View full text Add to dashboard Cite

| INTRODUC TI ONHelicobacter pylori infection of the gastric epithelial mucosa affects approximately 50% of the population worldwide. In developing countries, H pylori infection has been observed in more than 90% of the population because this infection remains asymptomatic in early childhood, resulting in an enormous economic burden on healthcare resources. 1,2 Standard triple antibiotic therapy (proton-pump inhibitor (PPI) in combination with two of the following: amoxicillin, clarithromycin, or metronidazole) has been the preferred initial approach for H pylori eradication. 3 However, due to increased resistance of H pylori to clarithromycin and/or metronidazole, the eradication rate with triple therapy has reduced to <70% presently, down from >90% observed in the 1990s. 4 In Japan, decreased eradication of H pylori with the Abstract Background: Probiotics are beneficial to patients with Helicobacter pylori infections by modulating the gut microbiota. Biofermin-R (BFR) is a multiple antibiotic-resistant lactic acid bacteria preparation of Enterococcus faecium 129 BIO 3B-R and is effective in normalizing the gut microbiota when used in combination with antibiotics. This study aimed to determine the effect of BFR in combination with vonoprazan (VPZ)based therapy on gut microbiota. Methods: Patients with positive urinary anti-H pylori antibody test (primary test) and fecal H pylori antigen test (secondary test) were examined. Patients in group 1 (BFR − )received VPZ (20 mg twice daily), amoxicillin (750 mg twice daily), and clarithromycin (400 mg twice daily) for 7 days. Patients in group 2 (BFR + ) received BFR (3 tablets/ day) for 7 days, in addition to the aforementioned treatments. Following treatment, the relative abundance, α-diversity, and β-diversity of gut microbiota were assessed.Results: Supplementation with BFR prevented the decrease in α-diversity after eradication therapy (Day 7). β-diversity was similar between groups. The incidence rate of diarrhea was non-significantly higher in the BFR − than in the BFR + group (73.1% vs 56.5%; P = .361). Stool consistency was comparable in the BFR + group on Days 7 and 1 (3.86 ± 0.95 vs 3.86 ± 1.46; P = .415). Conclusion:Biofermin-R combined with VPZ-based therapy resulted in higher microbial α-strain diversity and suppressed stool softening during H pylori eradication therapy. K E Y W O R D S Biofermin-R, gut microbiota, Helicobacter pylori, vonoprazan S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Kakiuchi T, Mizoe A, Yamamoto K, et al. Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial. Helicobacter. 2020;25:e12690.

show abstract

Identification ofLactobacillus ruminus SPM0211 isolated from healthy Koreans and its antimicrobial activity against some pathogens

et al. 2005

View full text Add to dashboard Cite

The intestinal microbiota are important to the host with regard to resistance they impart against bacterial infections and their involvement in mediating metabolic functions. Lactic acid producing bacteria such as Lactobacillus play an important physiological role in these matters. The aim of the present study was to isolate Lactobacillus sp. that inhibits enteric pathogens. Initially, 17 isolates from healthy Koreans were collected on Lactobacillus selective medium. Resistance of the isolates to antibiotics including rifampicin, streptomycin, clindamycin and vancomycin was measured. One of the isolate was identified as Lactobacillus ruminus on the basis of bacterial cell morphology, cultural characteristic and biochemical characteristics, 16S rRNA sequence analysis and PCR-RAPD. Antimicrobial activity of the bacterium against Vancomycin Intermediate Resistant Staphylococcus aureus (VISA) and Vancomycin-Resistant Enterococci (VRE) was measured. About 10(4) cells of VISA or VRE were mixed with 1, 5, and 9 mL of L. ruminus SPM 0211 and the final volume was adjusted to 10 mL with brain heart infusion (BHI) broth. The cell suspension was incubated for 3, 6, 9, and 24 h, serially diluted and then plated on BHI agar plates. As numbers of L. ruminus SPM 0211 were increased, viable cell count of VISA and VRE decreased. The strongest antimicrobial activity of SPM 0211 was observed after 9 h incubation in any mixture, almost completely inhibiting the growth of these two bacteria. The results suggest that the freshly isolated L. ruminus SPM 0211 may be used as a pro-biotic microbe that prevents the colonization of enteric pathogens and can thereby promote good gastrointestinal health.

show abstract

Effects of Biofermin-R Administered in Combination with Antibiotics on the Fecal Flora

Cited by 4 publications

References 0 publications

The effects of Bifidobacterium bifidum OFR9, a strain resistant to antituberculosis and antileprosy agents, on fecal flora in mice.

The effects of Bifidobacterium bifidum OFR9, a strain resistant to antituberculosis and antileprosy agents, on fecal flora in mice.

Effect of probiotics during vonoprazan‐containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial

Identification ofLactobacillus ruminus SPM0211 isolated from healthy Koreans and its antimicrobial activity against some pathogens

Contact Info

Product

Resources

About